For This Small Bio, a Heap of Events in the Second Half
Research - This small biotech company has three trials reading out in the second half of this year. First up, a phase 3 pivotal sometime this quarter.
Premium: Read NowzPremium
Be Prepared, FDA to Hand Down Approval Decision for ACelRx Next Month
Research - AcelRx (ACRX) will receive an approval decision form the US FDA next month for Zalviso. Read more, and understand our point of view, here.
Premium: Read Now
Two Technical Setups with Quality Fundamental Backstories
Research - Two technical trade ideas, both names PropThink has followed for some time, with quality, fundamental backstories.
Premium: Read Now
Orexigen Breaks Seven Dollars With PDUFA One Day Out
Research - Orexigen Therapeutics (OREX) broke above $7 in the Tuesday trading session, a day before the FDA issues a decision on the New Drug Application for NB32 (Contrave) as … Continue Reading
Premium: Read Now
The Retrophin Catch-22
Research - Retrophin management has pinned shareholders and potential investors between a rock and a hard spot, but there's reason to be optimistic.
Premium: Read Now
Antibiotic Incentives Loom, Cubist Still Positioned to Benefit
Research - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read Now
Obesity Déjà vu: Orexigen’s Approval Decision is Next Month
Research - Orexigen's (OREX) PDUFA data is next month for NB32. The stock is off 30% from its highs, and given a high chance of an approval, the long trade is attractive.
Read Now